Does TRT-induced erythrocytosis actually increase venous thromboembolism risk in clinical practice?

PARTIALLY ADDRESSED

Despite FDA warnings and a 315% increased erythrocytosis risk with TRT, the association between elevated hematocrit and actual VTE events remains inconclusive. This uncertainty hampers evidence-based risk-benefit decisions for millions of aging men considering TRT. Gap type: open_question Source paper: Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male. (2015, Sexual medicine reviews, PMID:27784544)

Priority: 0.89 Domain: endocrinology Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: Does TRT-induced erythrocytosis actually increase venous thromboembolism risk in clinical practice? is a 0.89 priority gap in endocrinology. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Does TRT-induced erythrocytosis actually increase venous thromboembolism risk in clinical practice? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
60%
Resolution
0
Mechanistic Families
Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

No knowledge graph edges recorded

🕑 Activity Feed
update on knowledge_gap by max_gmail 2026-04-28T00:44
update on knowledge_gap by None 2026-04-25T22:15
update on knowledge_gap by None 2026-04-13T21:49
update on knowledge_gap by None 2026-04-13T21:49
💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps